<DOC>
	<DOC>NCT02070744</DOC>
	<brief_summary>The objective of this study is to evaluate the safety and efficacy of VX-661in combination with ivacaftor in subjects with cystic fibrosis (CF) who are homozygous for F508del CFTR (cystic fibrosis transmembrane conductance regulator) mutation</brief_summary>
	<brief_title>Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Homozygous for the F508del CFTR mutation FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height Stable CF disease as judged by the investigator History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject Pregnant and nursing females: Females of childbearing potential must have a negative pregnancy test at screening and Day 1 Sexually active subjects of reproductive potential who are not willing to follow the contraception requirements The subject or a close relative of the subject is the investigator or sub investigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>CF</keyword>
</DOC>